Literature DB >> 6608006

Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection.

S Crawford, S P Goff.   

Abstract

A collection of mutants of Moloney murine leukemia virus with deletions in the gag gene was generated by restriction enzyme site-directed mutagenesis of a cloned proviral DNA. The mutants all contained deletions of the NarI site in the P12 region, and some contained deletions extending into the adjacent P15 region. The deletions did not significantly affect the assembly or release of viral particles. Examination of endogenous reverse transcription products demonstrated normal synthesis of minus- and plus-strand strong-stop DNAs, indicating that the RNA genome was packaged and that reverse transcription in detergent-permeabilized virions was not impaired. The virion particles contained high levels of an abnormal protein which corresponded to a P15-P12 fusion protein; proteolytic processing of this abnormal protein was completely blocked by all the mutations. The infectivity of the particles was dramatically reduced. Analysis of the low-molecular-weight DNA in infected NIH/3T3 cells indicated that the mutant virions could not carry out viral DNA synthesis. These data suggest that the P12 and P15 proteins may not be critical for virion assembly but do play an important role in early steps of viral infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608006      PMCID: PMC255553     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Identification of retrovirus matrix proteins by lipid-protein cross-linking.

Authors:  R B Pepinsky; V M Vogt
Journal:  J Mol Biol       Date:  1979-07-15       Impact factor: 5.469

2.  Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus.

Authors:  S Oroszlan; L E Henderson; J R Stephenson; T D Copeland; C W Long; J N Ihle; R V Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

3.  The relative hydrophobicity of oncornaviral structural proteins.

Authors:  S L Marcus; S W Smith; J Racevskis; N H Sarkar
Journal:  Virology       Date:  1978-05-15       Impact factor: 3.616

4.  Synthesis of a 600-nucleotide-long plus-strand DNA by virions of Moloney murine leukemia virus.

Authors:  S W Mitra; S Goff; E Gilboa; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

6.  Preparative and analytical purification of DNA from agarose.

Authors:  B Vogelstein; D Gillespie
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Phosphorylation of murine type C viral p12 proteins regulates their extent of binding to the homologous viral RNA.

Authors:  A Sen; C J Sherr; G J Todaro
Journal:  Cell       Date:  1977-03       Impact factor: 41.582

8.  Membrane properties of the gag gene-coded p15 protein of mouse type-C RNA tumor viruses.

Authors:  M Barbacid; S A Aaronson
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

9.  Restriction endonuclease cleavage of linear and closed circular murine leukemia viral DNAs: discovery of a smaller circular form.

Authors:  F K Yoshimura; R A Weinberg
Journal:  Cell       Date:  1979-02       Impact factor: 41.582

10.  High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections.

Authors:  A Shields; W N Witte; E Rothenberg; D Baltimore
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

View more
  41 in total

1.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

3.  Structural analysis of membrane-bound retrovirus capsid proteins.

Authors:  E Barklis; J McDermott; S Wilkens; E Schabtach; M F Schmid; S Fuller; S Karanjia; Z Love; R Jones; Y Rui; X Zhao; D Thompson
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

4.  Interaction of Moloney murine leukemia virus matrix protein with IQGAP.

Authors:  Juliana Leung; Andrew Yueh; Frank S K Appah; Bing Yuan; Kenia de los Santos; Stephen P Goff
Journal:  EMBO J       Date:  2006-04-20       Impact factor: 11.598

5.  Matrix protein of Akv murine leukemia virus: genetic mapping of regions essential for particle formation.

Authors:  E C Jørgensen; F S Pedersen; P Jørgensen
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Profile of Stephen P. Goff. Interview by Greg Williams.

Authors:  Stephen P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

8.  RNA dimerization defect in a Rous sarcoma virus matrix mutant.

Authors:  L J Parent; T M Cairns; J A Albert; C B Wilson; J W Wills; R C Craven
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Random screening for dominant-negative mutants of the cytomegalovirus nuclear egress protein M50.

Authors:  Brigitte Rupp; Zsolt Ruzsics; Christopher Buser; Barbara Adler; Paul Walther; Ulrich H Koszinowski
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

10.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.